Regeneron Gets CHMP Backing of Linvoseltamab
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
Feb. 24 meeting of the full Nassau County Legislature, Deputy Minority Leader Arnold W. Drucker honored District 16's seven ...
Shares of Regeneron Pharmaceuticals Inc. REGN shed 2.28% to $706.94 Wednesday, on what proved to be an all-around mixed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback